{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:30:20Z","timestamp":1793961020152,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.eprac.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:38:19Z","timestamp":1782862699000},"page":"1657-1666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-4947","authenticated-orcid":false,"given":"Toshitaka","family":"Sawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kometani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Karashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.06.008_bib1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/dc24-0011","article-title":"Increasing medication use and polypharmacy in type 2 diabetes: the Danish experience from 2000 to 2020","volume":"47","author":"Johansson","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.06.008_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14406","article-title":"Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch diabetes pearl cohort","volume":"38","author":"van Oort","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.eprac.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s40520-022-02165-1","article-title":"Prevalence and impact of polypharmacy in older patients with type 2 diabetes","volume":"34","author":"Remelli","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.eprac.2026.06.008_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109097","article-title":"Polypharmacy and bone fracture risk in patients with type 2 diabetes: the Fukuoka diabetes registry","volume":"181","author":"Komorita","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"supplement","key":"10.1016\/j.eprac.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjmed.2009.03.015","article-title":"Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use","volume":"122","author":"Kendall","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.eprac.2026.06.008_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1366368","article-title":"Current barriers to initiating insulin therapy in individuals with type 2 diabetes","volume":"15","author":"Gald\u00f3n Sanz-Pastor","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.06.008_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SurPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.06.008_bib11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s40200-024-01472-w","article-title":"Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study","volume":"23","author":"Sawamura","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.eprac.2026.06.008_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s13300-025-01704-z","article-title":"Insulin sensitivity and beta-cell function following tirzepatide in Japanese patients with type 2 diabetes: a SurPASS J-mono analysis","volume":"16","author":"Hamamoto","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.06.008_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2169\/internalmedicine.5779-25","article-title":"Two cases of diabetes remission through temporary tirzepatide treatment","volume":"65","author":"Sawamura","year":"2026","journal-title":"Intern Med"},{"key":"10.1016\/j.eprac.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11892-023-01532-0","article-title":"Factors influencing medication adherence among adults living with diabetes and comorbidities: a qualitative systematic review","volume":"24","author":"Gow","year":"2024","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.eprac.2026.06.008_bib15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s13300-025-01755-2","article-title":"Association between baseline Diabetes Therapy-Related Quality of Life (DTR-QOL) and subsequent risk of all-cause mortality: a prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 1633\u201348])","volume":"16","author":"Nishioka","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.06.008_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2337\/dbi19-0005","article-title":"GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family","volume":"68","author":"Nauck","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.eprac.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108779","article-title":"Tirzepatide ameliorates eating behavior regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus","volume":"38","author":"Suzuki","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.eprac.2026.06.008_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70045","article-title":"Long-term effectiveness of once-weekly semaglutide in patients with type 2 diabetes previously treated with insulin. A multicentre real-world study","volume":"41","author":"Bonora","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.eprac.2026.06.008_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3082","article-title":"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis","volume":"35","author":"Castellana","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.eprac.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2026.06.008_bib22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s13300-024-01620-8","article-title":"Tirzepatide improved health-related quality of life compared with insulin lispro in basal insulin-treated adults with type 2 diabetes and inadequate glycaemic control: a randomised controlled Phase 3b trial (SURPASS-6)","volume":"15","author":"Boye","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.16057","article-title":"De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: a single-centre, open-label randomised trial (TRANSITION-T2D)","volume":"27","author":"Rodriguez","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1152284","article-title":"Investigation of treatment satisfaction and health-related quality of life after add-on to metformin-based therapy in patients with type 2 diabetes","volume":"11","author":"Chang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.eprac.2026.06.008_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251372294","article-title":"The role of medication regimen complexity in diabetes management: a rapid review","volume":"16","author":"Khayyat","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib28","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s13300-024-01645-z","article-title":"Quality of life in Japanese people with type 2 diabetes switching from multiple daily insulin injections to once-daily iGlarLixi: SIMPLIFY Japan","volume":"15","author":"Ishii","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/dom.15446","article-title":"Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: an exploratory subgroup analysis of SurPASS-AP-Combo","volume":"26","author":"Ma","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s13300-024-01561-2","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes: analysis of SurPASS-AP-Combo by different subgroups","volume":"15","author":"Bi","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eprac.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis","volume":"56","author":"Kim","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/dom.12293","article-title":"Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis","volume":"16","author":"Kim","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41588-018-0332-4","article-title":"Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population","volume":"51","author":"Suzuki","year":"2019","journal-title":"Nat Genet"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:09:35Z","timestamp":1793959775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1530891X26010426"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.008","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}